NCT01554371View on ClinicalTrials.gov

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 27, 2012

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Malignant Solid TumourBreast Cancer Nos Metastatic RecurrentNeuropathy
Interventions
DRUG

Eribulin

"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"

DRUG

Cyclophosphamide

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT01554371 - Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter